Research programme: hepatitis B vaccine - GeoVax Labs
Latest Information Update: 13 Jul 2021
At a glance
- Originator GeoVax Labs
- Developer Georgia State University; Peking University Shenzhen Graduate School
- Class Hepatitis B vaccines; Synthetic vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 07 Jul 2021 Preclinical development in Hepatitis B is ongoing in USA (Parenteral)
- 07 Jul 2021 GeoVax Labs has patent protection for the compositions and methods hepatitis B vaccine in USA
- 28 Apr 2021 No recent reports of development identified for preclinical development in Hepatitis-B in USA (Parenteral)